S26948

a racemate of dimethyl-2-(4-(2-(6-benzoyl-2-oxo-1,3-benzothiazol-(2H)yl)ethoxy)benzyl)malonate; peroxisome proliferator activated receptor gamma modulator

Networked: 1 relevant articles (1 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Berthelot, Pascal: 1 article (04/2009)
2.	Caignard, Daniel-Henri: 1 article (04/2009)
3.	Caüzac, Michèle: 1 article (04/2009)
4.	Clément, Laurence: 1 article (04/2009)
5.	Consortium of the French Ministry of Research and Technology: 1 article (04/2009)
6.	Cruciani-Guglielmacci, Céline: 1 article (04/2009)
7.	Dacquet, Catherine: 1 article (04/2009)
8.	Kassis, Nadim: 1 article (04/2009)
9.	Ktorza, Alain: 1 article (04/2009)
10.	Lebègue, Nicolas: 1 article (04/2009)

Related Diseases

1.

Insulin Resistance 04/17/2009 - "Our data show that non thiazolidinedione S26948 may represent an alternative way for the management of dysregulated hepatic insulin sensitivity." 04/17/2009 - "S26948, a new specific peroxisome proliferator activated receptor gamma modulator improved in vivo hepatic insulin sensitivity in 48 h lipid infused rats." 04/17/2009 - "We examined whether S26948, a new specific peroxisome proliferator activated receptor gamma modulator prevented insulin-resistance induced by a 48 h intralipid-infusion in normal rat (IL rats). " 04/17/2009 - "However, S26948 specifically improved hepatic insulin sensitivity whereas rosiglitazone improved both hepatic insulin sensitivity and insulin-stimulated glucose utilization. "

Related Drugs and Biologics

1.	PPAR gamma
2.	Lipids
3.	Insulin (Novolin)
4.	Glucose (Dextrose)
5.	Rosiglitazone (Avandia)
6.	phospholipid emulsion soybean oil (Intralipid)
7.	2,4-thiazolidinedione (thiazolidinedione)